巨噬细胞移动抑制因子
血管生成
癌症研究
血管内皮生长因子
医学
细胞生长
脐静脉
血管内皮生长因子A
巨噬细胞
药理学
免疫学
细胞因子
病理
化学
血管内皮生长因子受体
体外
生物化学
作者
Xixun Yu,Jing‐biao Wu,Hao Fan,Li Dai,Hong‐chun Xian,Bing‐jun Chen,Peng Liao,Mei‐chang Huang,Xin Pang,Mei Zhang,Xin‐hua Liang,Ya‐ling Tang
摘要
Tumour vascular normalisation therapy advocates a balance between pro-angiogenic factors and anti-angiogenic factors in tumours. Artemisinin (ART), which is derived from traditional Chinese medicine, has been shown to inhibit tumour growth; however, the relationship between ART and tumour vascular normalisation in oral squamous cell carcinoma (OSCC) has not been previously reported.Different concentrations(0 mg/kg, 25 mg/kg, 50 mg/kg, 100 mg/kg)of ART were used to treat the xenograft nude mice model of OSCC. The effects of ART on migration and proliferation of OSCC and human umbilical vein endothelial cells (HUVEC) cells were detected by scratch assay and CCK-8 assay. OSCC cells with macrophage migration inhibitory factor (MIF) silenced were constructed to explore the effect of MIF.Treatment with ART inhibited the growth and angiogenesis of OSCC xenografts in nude mice and downregulated vascular endothelial growth factor (VEGF), IL-8, and MIF expression levels. ART reduced the proliferation, migration, and tube formation of HUVEC, as well as the expression of VEGFR1 and VEGFR2. When the dose of ART was 50 mg/kg, vascular normalisation of OSCC xenografts was induced. Moreover, VEGF and IL-8 were needed in rhMIF restoring tumour growth and inhibit vascular normalisation after the addition of rhMIF to ART-treated cells.Artemisinin might induce vascular normalisation and inhibit tumour growth in OSCC through the MIF-signalling pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI